Lung cancer (LC) is among the most fatal types of cancer. This requires finding new treatments which can target its main contributing etiological processes. Furthermore, radiotherapy (RT), while an important treatment, may also cause
inflammation associated with pain and fatigue. Such inflammation may also inadvertently further serve replication of surviving tumor cells. Research shows that the vagus nerve inhibits inflammation, oxidative stress and sympathetic
activity, all cancer-promoting processes. High vagal nerve activity independently predicts better prognosis in cancers including LC. Finally, a vagal-dependent anti-inflammatory drug reduced metastases in tumor-bearing mice. This study
will first pilot effects of combining non-invasive vagal nerve stimulation (VNS) and RT versus RT and usual care (control) on fatigue, pain and inflammation in stages 3A-3B LC. We will then test in a randomized-controlled trial effects
of non-invasive VNS on fatigue, pain, inflammation (IL-6, CRP), quality of life, metastasis in vital organs (brain, liver and lungs) and on overall survival, in 80 patients with stages 3A-3B LC. Results of this study could reveal
neuromodulation of tumors and possibly propose a novel cancer therapy for LC.
Effective start/end date1/10/1630/09/20

    Research areas

  • lung cancer

ID: 25893964